Emerald Medical Applications Corp. (OTCMKTS:MRLA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On March 26, 2017, the Board of Directors of Emerald Medical
Applications Corp. (the Registrant) received a letter of
resignation from Mrs. Adi Zamir, the Registrant’s CEO. In her
letter of resignation, Mrs. Adi Zamir stated that she would
continue to serve as CEO for up to 90 days. The Registrant filed
a Form 8-K on April 10, 2017 reporting Mrs. Zamir’s planned
resignation to become effective on June 23, 2017.
On May 14, 2017, Mrs. Zamir informed the Registrant’s Board of
Directors that she wished to have her resignation become
effective on May 14, 2017, rather than on June 23, 2017. The
Registrant’s Board of Directors accepted the resignation and is
most appreciative of the professional services and diligence
exhibited by Mrs. Zamir in the performance of her duties as CEO
through May 15, 2017.
Mrs. Zamir has informed the Registrant that she agrees with the
disclosure contained in this Form 8-K/A.
Item 9.01 Financial Statements and Exhibits.
(a) The following documents are filed as exhibits to this report
on Form 8-K or incorporated by reference herein. Any document
incorporated by reference is identified by a parenthetical
reference to the SEC filing that included such document.
|
Exhibit No. |
Description |
| 17.7 |
Letter of Resignation of Adi Zamir dated March 26, 2017, filed as an exhibit to the Registrant’s Form 8-K on April 10, 2017. |
About Emerald Medical Applications Corp. (OTCMKTS:MRLA)
Emerald Medical Applications Corp. operates through its subsidiary, Emerald Medical Applications Ltd. (Emerald), which is a digital health company. Emerald is engaged in the development, sale and service of imaging solutions utilizing its DermaCompare software that it developed for use in derma imaging and analytics. Emerald’s DermaCompare solution allows dermatologists and other medical care professionals, using a set of total body photography (TBP), to capture sets of skin lesion images with, among other devices, digital cameras, camera-equipped smartphones or tablets. DermaCompare imaging solution is provided as a software platform for early detection of Melanoma for classification of dermatological lesions as published by the National Institute of Health (NIH) for analysis of moles. DermaCompare imaging software solution reads and extracts data from those images and in essence turns digital camera, camera-equipped smartphones and tablets into virtual scanning devices. Emerald Medical Applications Corp. (OTCMKTS:MRLA) Recent Trading Information
Emerald Medical Applications Corp. (OTCMKTS:MRLA) closed its last trading session down -0.0110 at 0.0890 with 41,258 shares trading hands.
